Activating agent for peroxisome proliferator activated receptor
By designing new PPARδ activator compounds, we solve the problem of insufficient activity of existing PPARδ activators, achieve significant PPARδ transcriptional activation effects, and provide new drug candidates for the treatment of various metabolic and lipid-related diseases.
Patent Information
- Application Number
- CN201210028609.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2006-04-18
- Filing Date
- 2007-04-18
- Publication Date
- 2012-08-22
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Existing PPARδ activator compounds have deficiencies in structure and activity. In particular, the activity of phenylpropionic acid-type compounds is 30 times weaker than that of phenoxyacetic acid-type compounds, and the efficacy of phenylglycine-type compounds has not been fully explored.
A new type of compounds of general formulas (I), (II) and (III) was developed as an activator of PPARδ. Through specific molecular structure design, it significantly improved the transcriptional activation effect of PPARδ and became a powerful PPARδ agonist.
These compounds exhibit excellent PPARδ activating effects, surpassing the effects of traditional compounds, and have potential application value in the treatment and prevention of lipid abnormalities, metabolic syndrome, obesity, atherosclerosis, diabetes and other diseases.